ヤヌスキナーゼ（JAK）阻害薬の世界市場レポート2025年

ヤヌスキナーゼ（JAK）阻害薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.5%で99億3,000万米ドルに成長します。予測期間における成長の原動力は、免疫疾患に対する治療選択肢の拡大、承認された適応症の増加、患者の認識と教育の向上、治療へのアクセスの改善、免疫療法の重視の高まりにあるとみられます。主な動向としては、経口療法へのシフト、デジタル治療薬の統合、戦略的パートナーシップと提携、併用療法の発展、研究開発への投資の高まりなどが挙げられます。

自己免疫疾患の有病率の上昇は、ヤヌスキナーゼ（JAK）阻害薬市場の今後の成長を牽引すると予想されます。自己免疫疾患は、免疫系が誤って身体の健康な細胞や組織を攻撃することで発症します。このような疾患の増加は遺伝的要因の影響を受けており、特定の素因によって免疫機能障害を起こしやすくなっています。JAK阻害剤は、免疫シグナル伝達に関与する特定の酵素を標的としてブロックすることにより、炎症を抑え、免疫介在性の組織損傷を防ぐ。例えば、2024年6月、オーストラリア保健福祉研究所の報告によると、オーストラリアにおける関節リウマチによる入院患者数は、2021-22年には1万人に達し、前年の8,000人から25％増加しました。その結果、自己免疫疾患の有病率の増加がJAK阻害剤の需要を促進しています。

ヤヌスキナーゼ（JAK）阻害薬市場で事業を展開する主要企業は、治療適応の拡大、市場参入の加速、競争力の強化のため、薬事承認の取得に注力しています。薬事承認とは、特定の病状に対する安全性と有効性を確認した上で、医薬品の販売・マーケティングを許可する保健当局による公的認可のことです。例えば、2025年4月、米国のバイオ医薬品会社であるアッヴィ・インクは、経口JAK1選択的阻害剤であるRINVOQ（ウパダシチニブ）について、成人の巨細胞性動脈炎（GCA）の治療薬としてFDAの承認を取得しました。ウパダシチニブは、免疫介在性疾患および炎症性疾患に関与する炎症性サイトカインからのシグナルを伝達するJAK-STATシグナル伝達経路を阻害することにより作用します。今回の承認は、しばしば重大な副作用を伴うグルココルチコイドへの依存を軽減し、GCA管理における重要なアンメット・ニーズに対応し、患者の転帰を改善する貴重な新しい治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のヤヌスキナーゼ（JAK）阻害薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヤヌスキナーゼ（JAK）阻害薬市場：成長率分析
• 世界のヤヌスキナーゼ（JAK）阻害薬市場の実績：規模と成長, 2019-2024
• 世界のヤヌスキナーゼ（JAK）阻害薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界のヤヌスキナーゼ（JAK）阻害薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のヤヌスキナーゼ（JAK）阻害薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• JAK1阻害剤
• JAK2阻害剤
• JAK3阻害剤
• その他のタイプ
• 世界のヤヌスキナーゼ（JAK）阻害薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的JAK阻害剤
• 非選択的JAK阻害剤
• 経口JAK阻害剤
• その他の薬物の種類
• 世界のヤヌスキナーゼ（JAK）阻害薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界のヤヌスキナーゼ（JAK）阻害薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 乾癬性関節炎
• 炎症性腸疾患
• アトピー性皮膚炎
• 潰瘍性大腸炎
• 世界のヤヌスキナーゼ（JAK）阻害薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のヤヌスキナーゼ（JAK）阻害薬市場JAK1阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィルゴチニブ
• ウパダシチニブ
• イタシチニブ
• アブロシチニブ
• ブレポシチニブ
• 世界のヤヌスキナーゼ（JAK）阻害薬市場JAK2阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェドラチニブ
• パクリチニブ
• モメロチニブ
• ガンドチニブ
• NS-018
• 世界のヤヌスキナーゼ（JAK）阻害薬市場JAK3阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トファシチニブ
• PF-06651600
• リトルシチニブ
• 世界のヤヌスキナーゼ（JAK）阻害薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バリシチニブ
• ルキソリチニブ
• オクラシチニブ
• デルゴシチニブ
• ペフィシチニブ

第7章 地域別・国別分析

• 世界のヤヌスキナーゼ（JAK）阻害薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヤヌスキナーゼ（JAK）阻害薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヤヌスキナーゼ（JAK）阻害薬市場：競合情勢
• ヤヌスキナーゼ（JAK）阻害薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Incorporated
• Incyte Corporation
• Galapagos NV
• Theravance Biopharma Inc.
• Celon Pharma S.A.
• Aclaris Therapeutics Inc.
• Arcutis Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヤヌスキナーゼ（JAK）阻害薬市場2029：新たな機会を提供する国
• ヤヌスキナーゼ（JAK）阻害薬市場2029：新たな機会を提供するセグメント
• ヤヌスキナーゼ（JAK）阻害薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Janus kinase (JAK) inhibitor drugs are medications designed to block the activity of Janus kinases-enzymes that play a key role in immune system signaling and inflammatory pathways. By inhibiting these enzymes, JAK inhibitors help control overactive immune responses, making them effective in the treatment of autoimmune and inflammatory disorders.

The primary types of Janus kinase (JAK) inhibitors include JAK1, JAK2, JAK3 inhibitors, and other variants. JAK1 inhibitors specifically target the JAK1 enzyme, which is critical in immune cell signaling, and are widely used for managing conditions such as rheumatoid arthritis and atopic dermatitis. These drugs are available in several forms, including selective and non-selective inhibitors, and are administered via oral, injectable, or topical routes. Key therapeutic applications span rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and atopic dermatitis. The end users include hospitals, home care settings, specialty clinics, and other healthcare facilities.

The janus kinases JAKs inhibitor drug market research report is one of a series of new reports from The Business Research Company that provides janus kinases JAKs inhibitor drug market statistics, including janus kinases JAKs inhibitor drug industry global market size, regional shares, competitors with a janus kinases JAKs inhibitor drug market share, detailed janus kinases JAKs inhibitor drug market segments, market trends and opportunities, and any further data you may need to thrive in the janus kinases JAKs inhibitor drug industry. This janus kinases JAKs inhibitor drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The janus kinases (JAKs) inhibitor drug market size has grown rapidly in recent years. It will grow from $5.74 billion in 2024 to $6.42 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth during the historic period was driven by the increasing prevalence of autoimmune diseases, expansion of Janus kinase (JAK) inhibitors' applications beyond rheumatoid arthritis, the aging global population, and favorable reimbursement policies supporting wider access to treatment.

The janus kinases (JAKs) inhibitor drug market size is expected to see rapid growth in the next few years. It will grow to $9.93 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period is expected to be driven by expanding treatment options for immunological diseases, a rising number of approved indications, increased patient awareness and education, improved accessibility to therapies, and a growing emphasis on immunotherapy. Key trends include a shift toward oral therapies, integration of digital therapeutics, strategic partnerships and collaborations, advances in combination therapies, and heightened investment in research and development.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Janus kinase (JAK) inhibitor drug market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues. This increasing prevalence is influenced by genetic factors, as certain predispositions make individuals more susceptible to immune dysfunction. JAK inhibitors target and block specific enzymes involved in immune signaling, thereby reducing inflammation and preventing immune-mediated tissue damage. For instance, in June 2024, a report by the Australian Institute of Health and Welfare revealed that hospitalizations for rheumatoid arthritis in Australia rose to 10,000 in 2021-22, a 25% increase from 8,000 the previous year, corresponding to 39 hospitalizations per 100,000 population. Consequently, the growing prevalence of autoimmune diseases is propelling demand for JAK inhibitor drugs.

Major companies operating in the Janus kinase (JAK) inhibitor drug market are focusing on securing regulatory approvals to expand therapeutic indications, accelerate market entry, and strengthen their competitive position. Regulatory approvals are official authorizations granted by health authorities permitting the marketing and sale of drugs after confirming their safety and efficacy for specific medical conditions. For example, in April 2025, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for RINVOQ (upadacitinib), an oral JAK1-selective inhibitor, for treating adults with giant cell arteritis (GCA). Upadacitinib works by disrupting the JAK-STAT signaling pathway, which transmits signals from pro-inflammatory cytokines involved in immune-mediated and inflammatory diseases. This approval provides a valuable new treatment option that reduces dependence on glucocorticoids-often linked to significant side effects-thus addressing a critical unmet need in GCA management and improving patient outcomes.

In July 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired Sierra Oncology for $1.9 billion. This acquisition aims to strengthen GSK's specialty medicines portfolio by gaining access to momelotinib, a differentiated late-stage therapy that addresses significant unmet medical needs in myelofibrosis patients with anemia. The deal expands GSK's capabilities in hematology and offers meaningful new benefits to patients. Sierra Oncology, based in the US, develops momelotinib, a selective oral inhibitor of Janus kinases (JAK1 and JAK2) and ACVR1, specifically for treating myelofibrosis.

Major players in the janus kinases (jaks) inhibitor drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Galapagos NV, Theravance Biopharma Inc., Celon Pharma S.A., Aclaris Therapeutics Inc., Arcutis Biotherapeutics Inc., Dizal (Jiangsu) Pharmaceutical Co. Ltd., Reistone Biopharma Co. Ltd.

North America was the largest region in the janus kinases (JAKs) inhibitor market in 2024. The regions covered in janus kinases (JAKs) inhibitor drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the janus kinases (JAKs) inhibitor drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The janus kinases (JAKs) inhibitor drug market consists of sales of oral tablets, oral capsules, topical formulations, injectable forms, and additional JAK inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Janus Kinases (JAKs) Inhibitor Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on janus kinases (jaks) inhibitor drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for janus kinases (jaks) inhibitor drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The janus kinases (jaks) inhibitor drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: JAK1 Inhibitor; JAK2 Inhibitor; JAK3 Inhibitor; Other Types
• 2) By Drug Type: Selective JAK Inhibitors; Non-Selective JAK Inhibitors; Oral JAK Inhibitors; Other Drug Types
• 3) By Route of Administration: Oral; Injectable; Topical
• 4) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Inflammatory Bowel Disease; Atopic Dermatitis; Ulcerative Colitis
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By JAK1 Inhibitor: Filgotinib; Upadacitinib; Itacitinib; Abrocitinib; Brepocitinib
• 2) By JAK2 Inhibitor: Fedratinib; Pacritinib; Momelotinib; Gandotinib; NS-018
• 3) By JAK3 Inhibitor: Tofacitinib; PF-06651600; Ritlecitinib
• 4) By Other Types: Baricitinib; Ruxolitinib; Oclacitinib; Delgocitinib; Peficitinib
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Janus Kinases (JAKs) Inhibitor Drug Market Characteristics

3. Janus Kinases (JAKs) Inhibitor Drug Market Trends And Strategies

4. Janus Kinases (JAKs) Inhibitor Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Janus Kinases (JAKs) Inhibitor Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Janus Kinases (JAKs) Inhibitor Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Janus Kinases (JAKs) Inhibitor Drug Market Growth Rate Analysis
• 5.4. Global Janus Kinases (JAKs) Inhibitor Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Janus Kinases (JAKs) Inhibitor Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Janus Kinases (JAKs) Inhibitor Drug Total Addressable Market (TAM)

6. Janus Kinases (JAKs) Inhibitor Drug Market Segmentation

• 6.1. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• JAK1 Inhibitor
• JAK2 Inhibitor
• JAK3 Inhibitor
• Other Types
• 6.2. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective JAK Inhibitors
• Non-Selective JAK Inhibitors
• Oral JAK Inhibitors
• Other Drug Types
• 6.3. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.4. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Inflammatory Bowel Disease
• Atopic Dermatitis
• Ulcerative Colitis
• 6.5. Global Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK1 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgotinib
• Upadacitinib
• Itacitinib
• Abrocitinib
• Brepocitinib
• 6.7. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK2 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fedratinib
• Pacritinib
• Momelotinib
• Gandotinib
• NS-018
• 6.8. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of JAK3 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tofacitinib
• PF-06651600
• Ritlecitinib
• 6.9. Global Janus Kinases (JAKs) Inhibitor Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baricitinib
• Ruxolitinib
• Oclacitinib
• Delgocitinib
• Peficitinib

7. Janus Kinases (JAKs) Inhibitor Drug Market Regional And Country Analysis

• 7.1. Global Janus Kinases (JAKs) Inhibitor Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Janus Kinases (JAKs) Inhibitor Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market

• 8.1. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Janus Kinases (JAKs) Inhibitor Drug Market

• 9.1. China Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 9.2. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Janus Kinases (JAKs) Inhibitor Drug Market

• 10.1. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Janus Kinases (JAKs) Inhibitor Drug Market

• 11.1. Japan Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 11.2. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Janus Kinases (JAKs) Inhibitor Drug Market

• 12.1. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market

• 13.1. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Janus Kinases (JAKs) Inhibitor Drug Market

• 14.1. South Korea Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 14.2. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market

• 15.1. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 15.2. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Janus Kinases (JAKs) Inhibitor Drug Market

• 16.1. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Janus Kinases (JAKs) Inhibitor Drug Market

• 17.1. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Janus Kinases (JAKs) Inhibitor Drug Market

• 18.1. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Janus Kinases (JAKs) Inhibitor Drug Market

• 19.1. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Janus Kinases (JAKs) Inhibitor Drug Market

• 20.1. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market

• 21.1. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 21.2. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Janus Kinases (JAKs) Inhibitor Drug Market

• 22.1. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Janus Kinases (JAKs) Inhibitor Drug Market

• 23.1. North America Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 23.2. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Janus Kinases (JAKs) Inhibitor Drug Market

• 24.1. USA Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 24.2. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Janus Kinases (JAKs) Inhibitor Drug Market

• 25.1. Canada Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 25.2. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Janus Kinases (JAKs) Inhibitor Drug Market

• 26.1. South America Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 26.2. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Janus Kinases (JAKs) Inhibitor Drug Market

• 27.1. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Janus Kinases (JAKs) Inhibitor Drug Market

• 28.1. Middle East Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 28.2. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Janus Kinases (JAKs) Inhibitor Drug Market

• 29.1. Africa Janus Kinases (JAKs) Inhibitor Drug Market Overview
• 29.2. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Janus Kinases (JAKs) Inhibitor Drug Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Janus Kinases (JAKs) Inhibitor Drug Market Competitive Landscape And Company Profiles

• 30.1. Janus Kinases (JAKs) Inhibitor Drug Market Competitive Landscape
• 30.2. Janus Kinases (JAKs) Inhibitor Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Janus Kinases (JAKs) Inhibitor Drug Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Vertex Pharmaceuticals Incorporated
• 31.10. Incyte Corporation
• 31.11. Galapagos NV
• 31.12. Theravance Biopharma Inc.
• 31.13. Celon Pharma S.A.
• 31.14. Aclaris Therapeutics Inc.
• 31.15. Arcutis Biotherapeutics Inc.

32. Global Janus Kinases (JAKs) Inhibitor Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Janus Kinases (JAKs) Inhibitor Drug Market

34. Recent Developments In The Janus Kinases (JAKs) Inhibitor Drug Market

35. Janus Kinases (JAKs) Inhibitor Drug Market High Potential Countries, Segments and Strategies

• 35.1 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Janus Kinases (JAKs) Inhibitor Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer